We're moving into a time of year that’s been difficult for bulls, historically. However, if the market does sell off, Cramer won't cry.» Read More
Cramer believes there’s always opportunity in the market. You simply have to know where to look.
Perrigo CEO Joseph Papa provides insight on the current flu season, and how it plans on getting its name better known.
Perrigo CEO Joseph Papa discusses how its new headquarters in Ireland will impact its tax structure, and whether the company will add a dividend.
Jim Cramer has been a fan of this company for quite some time. But a good stock always needs new catalysts.
Investing is a bit like an Ellery Queen mystery. If you can follow the clues you should find what you're seeking - upside.
More large American corporations are reducing their tax bill by buying a foreign company and effectively renouncing their United States citizenship.
The Mad Money host always suggests watching for dips. But is the weakness in Perrigo really a buying opportunity?
Uncertainty about the Fed is making stocks nervous and is adding to a growing bearishness about the market.
A new development suggests big companies may be getting fed up with Washington. Really fed up.
Sick of high U.S. corporate taxes? Here's how some companies are slashing their tax bill by 10%, 20%—or more.
Who’s best for the markets, Yellen or Summers? Wall Street debates while awaiting Obama’s pick for the next Fed chairman.
Cramer says a trio of recent deals demands attention.
Stocks kicked off the week on a weak note as investors hesitated to jump in ahead of the Federal Reserve meeting and a slew of key economic reports.
This is a big week for macro news: a Federal Reserve meeting, an advance look at second-quarter U.S. growth, and July's nonfarm payroll report. But the bigger story may be the weakness of the U.S. dollar.
U.S. stock index futures ticked lower on Monday, ahead of the Federal Reserve meeting and another heavy week for second quarter earnings.
The Federal Reserve's taper talk may have rattled the financial markets but it has had one notable beneficiary: Mergers and acquisitions.
U.S. generic drugmaker Perrigo agreed to buy fellow drug company Elan for $8.6 billion on Monday in a deal that will hand it royalty rights from a blockbuster treatment and tax savings from being domiciled in Ireland.
Perrigo CEO Joe Papa discusses the biotech industry, the state of the consumer and why Mucinex is going to be a big winner for his company.
As the economy stalled, many people opted for store brand medicines. But as the economy improves, will the trend reverse?
The Forensic Accounting ETF launches today. The fund spotlights a concept that is often woefully overlooked.